Skip to content Skip to footer
Subscribe Now
Insights+: EMA Marketing Authorization of New Drugs in December 2023
INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in December 2023

Shots:  The EMA approved 3 BLA while 4 New Chemical Entities in December 2023, leading to treatments for patients and advances in the healthcare industry In December 2023, the major highlighted drugs were Jempreli to treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer and Zilbrysq for the treatment of Generalized Myasthenia Gravis   PharmaShots has compiled a list of a…
January 23, 2024

Read more

VIEWPOINTS_Thirusha Lane_2024
VIEWPOINTS

Breaking the Barriers of hATTR Treatment: Thirusha Lane Shares her Insightful Thoughts with PharmaShots

Shots:  Often, patient care focuses solely on therapeutics, but with rare diseases like hATTR amyloidosis, integrating holistic care for patients is crucial to ensure patients fully live their lives  In an enlightening conversation with PharmaShots, Thirusha Lane shares the highlights of the recommendations developed by the international panel of patient advocates and HCPs for people…
January 22, 2024

Read more

e-Brain OncoVision Connecting the Dots in Cancer Care
EVENTS

e-Brain OncoVision: Connecting the Dots in Cancer Care

Gear up for the most awaited metaverse-based global event!  Don’t miss out on this enlightening conference focussed on Oncology domains by Ingenious E-Brain.  The virtual event “e-Brain OncoVision: Connecting the Dots in Cancer Care” is scheduled for February 15th (9:00AM EST) to February 16th, 2024 (5:30PM EST)  Featuring renowned speakers from leading biopharma companies & organizations, the…
January 18, 2024

Read more

Exclusive_Noelle Bush_2024
EXCLUSIVE

Noelle Bush in an Enlightening Interview with PharmaShots Shares Insights from the It Takes 2 Awareness Program

Shots:  Exemplifying awareness campaign at its best with a hint of contemporary music, “It takes 2” by Boehringer Ingelheim and Eli Lilly is a noble initiative aimed at integrating UACR testing with eGFR for better screening of CKD  Noelle Bush, in an engaging conversation with PharmaShots, cites the growing incidences of CKD in the US.…
January 15, 2024

Read more

EVENTS

Post Collaboration: Laura Acosta and Himanshu Sehgal in a Candid Conversation

In pursuit of achieving data-driven excellence, PharmaShots came across Newstex. Soon, as a part of a collaboration PharmaShots and Newstex embarked on a journey to delivering high-quality and unerring content. Himanshu Sehgal, Director at PharmaShots, in a candid conversation with Newstex’s Head of Publisher Solutions, Laura Acosta. While sharing the origin story of PharmaShots, Himanshu…
January 11, 2024

Read more

Announcements

PharmaShots Announces New Content Partnership with Newstex 

PharmaShots is pleased to announce that we have entered into a new content partnership with Newstex, expanding the reach and impact of our insights across global professional and academic audiences.  This collaboration strengthens our mission to deliver high-quality, timely, and actionable biopharma and healthcare intelligence. By integrating PharmaShots’ curated industry updates into Newstex’s premium content distribution network, we aim to support researchers, analysts, students,…
January 11, 2024

Read more

VIEWPOINTS_Michael Moran1_Julie Blaedel2_2024
VIEWPOINTS

Julie Blaedel from Genmab and Michael Moran from AbbVie Discuss the Conditional EC Approval of TEPKINLY in a Stimulating Conversation with PharmaShots

Shots:    Diffuse large B-cell lymphoma remains the most common type of non-Hodgkin lymphoma. With limited therapeutic options for patients whose disease gets relapsed or refractory, AbbVie and Genmab’s TEPKINLY is one-of-a-kind monotherapy for adult patients with relapsed or refractory DLBCL   Post EC’s conditional approval, Julie Blaedel & Michael Moran engage in an enlightening conversation with…
January 10, 2024

Read more

VIEWPOINTS_Brian Quigley_2024
VIEWPOINTS

Tackling Pulmonary Infections: Brian Quigley Sheds Light on Qnovia’s Recent Partnership with the University of Virginia

Shots:  Following Qnovia’s recent partnership with the University of Virginia, Brian Quigley engages in a stimulating conversation with PharmaShots   The collaboration adds two assets, QN-05 for the treatment of pneumonia and QN-06 for the treatment of pulmonary infection caused by B. anthracis, to Qnovia’s portfolio   During a discussion of Qnovia's proprietary drug delivery platform RespiRx,…
January 8, 2024

Read more

ThoughtSpot_Saurabh Chaubey9
THOUGHTSPOT

Targeted Therapy in Oncology

Shots:  The oncology domain accounts for more than 50% of ongoing clinical trials. The global oncology drug market was valued at $185B in 2022 and is predicted to reach $205B by 2030 with a 13% CAGR   Targeted therapy targets specific genes and proteins to prevent them from growing and spreading. In 2022, the market size…
January 3, 2024

Read more

Insight+_Saurabh Chaubey
INSIGHTS+

Most Viewed Articles of 2023

2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.   Top 20 Radiopharma Companies Based on Market Cap  Shots:  Integrating scintigraphy with…
January 2, 2024

Read more

Load more